Novartis AG Sponsored ADR (NVS)
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy
Novartis AG (ADR) (NYSE:NVS) announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for allergic diseases. Under the agreement, Novartis will pay up to US$2 billion in upfront and milestone payments for Excellergy.
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Therapeutics for up to $3 billion to secure the rights to an experimental breast cancer drug.
Novartis to Buy Biotech Excellergy for Up to $2 Billion
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
Swiss pharma company Novartis said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion.
Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree
Novartis AG faces significant patent expiries but is aggressively acquiring pipeline assets, including a $2bn deal for Pikavation and a $12bn buyout of Avidity. NVS projects >5% annual revenue growth to ~$70bn by 2030, driven by eight de-risked assets and a robust late-stage pipeline, despite looming patent cliffs. Recent M&A activity, while raising questions about pipeline confidence, is viewed as strategic to offset $12bn in expiring revenues and maintain growth momentum.
Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth
Novartis maintains a 'Strong Buy' rating, driven by resilient 2025 sales growth of 8% to $54.53 billion and robust product performance. NVS is actively strengthening its pipeline with strategic acquisitions, notably the $3B Synnovation Therapeutics deal for SNV4818 targeting HR+/HER2- breast cancer. Despite significant 2026 patent expirations (Entresto, Promacta, Tasigna), NVS expects to achieve low single-digit sales growth, supported by seven key growth drivers.
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
SNV4818 is being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors, Novartis said.
Novartis to buy breast cancer drug candidate from Synnovation
Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development achievements.
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU approval.
Novartis, Genentech file suit alleging illegal importation of prescription drug
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and temperature controls, potentially puts patients at risk, the suit said.
